The title compound was prepared from 2‐nitrocyclodecanone (2). Compound 2 was treated with 2‐methylpro‐penal to give the Michael‐addition product 3 which was reduced to the alcohol 5 and the latter ring‐enlarged with Bu4NF to 12‐methyl‐10‐nitro‐13‐tridecanolide (6) followed by reductive elimination of the NO2 group by Bu3SnH.
No takes yet. Share an insight, caveat, or question.
Stanchev et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: